2022 SHS stands at the head of the tide, strives to be the first, discusses the frontier of blood, explores the road to the future, and the 15th Suzhou Hematology Summit is grandly held!

In front of the south window of Qiulan, the fragrance is quiet
.
On October 8, 2022, many top hematology experts at home and abroad gathered in Gusu City, a paradise on earth, to participate in the 15th Suzhou Hematology Summit
.
Since the establishment of the Suzhou Hematology Summit in 2008, this academic tradition has been upheld for 14 years, and it has become an important academic event in the field of hematology, sharing cutting-edge academic progress
for many colleagues in hematology and well-known scholars in the field.

With the theme of "Standing at the head of the tide and striving to be the first", the conference specially invited Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Academician Chen Saijuan of the Chinese Academy of Engineering, Academician Zhan Qimin of Suzhou Medical College of Soochow University and Chinese Academy of Engineering, Academician Wang Guangji of China Pharmaceutical University and Chinese Academy of Engineering, Academician Gu Xiaosong of the Ministry of Education of Nantong University and Chinese Academy of Engineering, and Philippe of the French Myeloma Working Group.
Professor Moreau, Professor Borje S.
Andersson of MD Anderson Cancer Center and other well-known experts at home and abroad gave wonderful academic reports, discussing "new progress, new theories and new technologies" in the field of hematology, showing the latest achievements from cutting-edge basic research to clinical practice, learning from each other's strengths and gaining new knowledge
.
Yimaitong has compiled the wonderful content of the conference to feed readers
.

Opening of the General Assembly

Professor Wu Depei delivered a speech

Under the chairmanship of Professor Wu Depei of the First Affiliated Hospital of Soochow University, Academician Ruan Changgeng, Director of Jiangsu Institute of Hematology, Professor Liu Jisheng, Secretary of the Party Committee and President of the First Affiliated Hospital of Soochow University, Tan Weiliang, President of Suzhou Medical Association, Academician Zhan Qimin, Dean of Suzhou Medical College of Soochow University, and Professor Zhang Xiaohong, Deputy Secretary of the Party Committee and President of Soochow University, delivered opening speeches
.

Academician Ruan Changgeng delivered a speech

Academician Ruan Changgeng said in his speech that since the establishment of the Suzhou Hematology Summit in 2008, many experts have gathered in Suzhou on the first weekend of October every year for academic exchanges
.
With the support of all sectors of society, the scale of the conference gradually expanded
.
This is the 15th Suzhou Hematology Summit, bringing together top hematology experts at home and abroad to conduct in-depth discussions
on precision medicine and leukemia transplantation, new drug research and development in hematology, big data platform construction, infection and severe diseases.
It is believed that this grand event can improve the diagnosis and treatment level and clinical research ability
of blood diseases in China.
It is hoped that all blood people will unite their efforts, forge ahead, continue to carry forward the health work spirit of "respecting life, saving life and helping the wounded, willing to dedicate, and boundless love", strengthen faith, continue to forge ahead, and escort the health of the people with higher morale, more solid work, and a more lofty attitude, and finally wish the conference a complete success!

Secretary Liu Jisheng delivered a speech

Secretary Liu Jisheng said in his speech that Boxi Hospital, the predecessor of the First Affiliated Hospital of Soochow University, was founded in 1883, and after 139 years of inheritance and development, integrity and innovation, with "Boxi innovation, moral integrity and welfare of people" as the hospital motto, with the efforts of generations of colleagues, the hospital has achieved gratifying results
in terms of scale, medical quality, talent team, scientific and technological innovation, clinical research, medical education, and cultural construction 。 The First Affiliated Hospital of Soochow University will continue to uphold the strategy of talent establishment, scientific and technological rejuvenation and quality hospitalization, explore the road of construction of a type of discipline, and hope to become a first-class, internationally renowned, high-level and characteristic research hospital as soon as possible

President Tam Wai Leung delivered a speech

President Tan Weiliang said in his speech that the Suzhou Hematology Summit is an important academic event in the field of hematology in China, and it is also a high-quality conference hosted by Suzhou Medical Association, which has played an important role
in promoting the progress of Suzhou medicine and the development of science and technology.
With the joint efforts of all experts, the field of hematology in Suzhou has been continuously developed and achieved excellent results, once again thank all the experts, and wish this conference a complete success!

Academician Zhan Qimin delivered a speech

Academician Zhan Qimin said in his speech that the autumn of Gusu is the most beautiful season in Suzhou, and experts gathered in the historical and cultural city to grandly hold the 2022 Suzhou Hematology Summit
.
Since its inception, the Suzhou Hematology Summit has built a good platform
for the exchange of the latest knowledge, theory and technology of hematology in China.
This conference focuses on the cutting-edge development of hematology, I believe that all experts can gain something in this conference, can better cohesion, and face the needs of national major disease prevention and treatment, clinical diagnosis and treatment of blood diseases, and basic research needs, and wish the conference a complete success!

President Zhang Xiaohong delivered a speech

President Zhang Xiaohong said in his speech that well-known experts and scholars from the field of hematology at home and abroad gathered in Suzhou, a thousand-year-old city known as a paradise on earth, to hold the 2022 Suzhou Hematology Summit
.
As the traditional advantageous discipline of Soochow University, the school regards it as a pillar discipline of strategy and builds it, establishes a high-level team with excellent quality, and has also achieved original achievements
with certain influence at home and abroad.
The Suzhou Hematology Summit has been successfully held for 15 sessions so far, which has played an important role
in promoting the development of hematology diagnosis and treatment and new technologies in China and even the world.
At this conference, domestic and foreign hematology experts gathered in Suzhou again to discuss the hot spots, key points and difficulties of the current discipline development, hoping that all experts and scholars will inspire each other, upgrade this summit to a high-level medical event with high level, great influence and wide benefits, further deepen exchanges and cooperation in the field of hematology at home and abroad, provide broader ideas for the development of hematology, and finally wish this conference a complete success!

Research and discussion on big data of leukemia in Jiangsu Province

Academician Chen Saijuan made a wonderful report

Co-chaired by Professor Huang Xiaojun of Peking University People's Hospital and Professor Hu Yu of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Academician Chen Saijuan deeply analyzed the big data
of leukemia in Jiangsu Province.

As of August 20, 2022, the registration system showed a total of 5,464 leukemia cases
in Jiangsu Province.
Epidemiological data at home and abroad show that the incidence of adult acute leukemia (AL) is age-related, the median age of adult new AL patients in Jiangsu Province is younger than that in the whole country, and Jiangsu Province receives more patients with long-distance leukemia, and strong blood diagnosis and treatment and transplantation ability is the main reason
for attracting non-provincial household registration leukemia patients to come for medical treatment.
The preliminary analysis results show that the 5-year survival rate of adult acute lymphoblastic leukemia (ALL) patients in Jiangsu Province is better than the national average, showing the advantages
of Jiangsu Province medical treatment in leukemia treatment.

In the future, it is urgent to carry out refined molecular typing, strengthen transcriptome sequencing technology (RNAseq), next-generation sequencing to detect fusion genes and gene mutations, so as to improve the level of molecular diagnosis and provide a basis
for targeted therapy based on molecular typing.
At the same time, RNAseq method can identify more molecular markers and gene mutations, accurately guide the risk stratification, prognosis and treatment of diseases, provide a basis for molecular targeted therapy, identify high-risk groups as soon as possible, and improve the treatment level of
patients.
In addition, as China enters an aging society, omics research will provide countermeasures for the prevention and treatment of leukemia in the elderly, and it is necessary to improve MCM detection (i.
e.
comprehensive cell morphology, immunology, cytogenetics, molecular biology technology) and omics detection
in the elderly.

Scientific and technological innovation helps the development of clinical medicine

Academician Zhan Qimin made a wonderful report

Under the co-chairmanship of Professor Ma Jun of Harbin Institute of Hematology and Oncology and Professor Wang Xin of Shandong Provincial Hospital, Academician Zhan Qimin gave a wonderful report
entitled "Scientific and Technological Innovation Helps the Development of Clinical Medicine".

The challenges in the development of China's health industry are mainly insufficient medical innovation capabilities and incomplete clinical research, and there is an urgent need to carry out high-quality, large-population, long-term clinical research (especially multi-center randomized controlled trial research), formulate safe and effective evidence and norms for disease prevention, diagnosis and treatment suitable for the characteristics of China's population, support clinical diagnosis and treatment, and improve clinical level
.
At the same time, disease prevention, diagnosis and treatment norms (clinical pathways, guidelines, expert consensus, etc.
) and related scientific and technological standards are standardized measures to guide clinical practice, and are the most important links
in the whole chain of medical science and technology innovation.
In addition, personalized diagnosis and treatment and biological therapy, big data and intelligent medicine will also be important means
to help precision tumor therapy.

Pharmaceutical integration to promote the high-quality development of cell therapy products

Academician Wang Guangji made a wonderful report

Co-chaired by Professor Miao Liyan of the First Affiliated Hospital of Soochow University and Professor Wang Jianxiang of the Hematology Hospital of the Chinese Academy of Medical Sciences, Academician Wang Guangji shared the wonderful sharing of "Medical Fusion, Promoting the High-quality Development of Cell Therapy Products
".

Compared with traditional chemical or antibody drugs, cell therapy has the advantage
of single-treatment, long-term benefit.
At present, the treatment of malignant hematological tumors has gradually entered the era
of live-cell drugs represented by chimeric antigen receptor T cell (CAR-T) immunotherapy and stem cell therapy.
At present, the in vivo process and efficacy mechanism of cell drugs are scientific problems that need to be solved urgently, and it is necessary to quantitatively analyze the in vivo distribution, migration and homing process
of living cells through nuclear molecular imaging.

In addition, the transformation from medical technology into cell drugs must be confirmed through standardized preclinical druggability evaluation such as pharmacy, pharmacokinetics, pharmacoefficacy, safety evaluation, etc.
, which has "safe, effective and quality controllable" drug properties, so the druggability evaluation of cell drugs is also a scientific problem
that needs to be solved urgently.
At present, a stem cell dual standard system that meets domestic and international standards has been formed, and a full-chain, closed-loop Good Manufacturing Practice (GMP) quality control system
has been established from umbilical cord collection to clinical use.

Construction of organizational engineering innovation and transformation platform

Academician Gu Xiaosong made a wonderful report

Under the co-chairmanship of Professor Liu Qiqi of Southern Hospital of Southern Medical University and Professor Li Jianyong of the First Affiliated Hospital of Nanjing Medical University, Academician Gu Xiaosong shared the "Construction of Organizational Engineering Innovation and Transformation Platform"
.

The "artificial tissue nerve graft" developed by Academician Gu Xiaosong's team has been the first to be applied in clinical practice at home and abroad, and the product composition structure of "peripheral nerve repair graft", a major scientific and technological achievement in tissue engineering neurological research, is the first at home and abroad, with good generalizability, and the product was approved for registration and marketing
by the State Medical Products Administration in November 2020.

Due to neurotrauma caused by trauma, work injury, traffic accident, tumor surgery, earthquake and natural disasters, etc.
, Academician Gu Xiaosong's team found that stem cells combined with artificial nerve grafts to repair long-distance nerve trunk defects have good results, and proposed the theory of molecular regulation of neuronal "regeneration stage", which enriched the theoretical theory of molecular regulation after nerve injury, and made people's understanding of nerve injury and regeneration enter a new stage
of molecular regulation from morphological definition.

Induction Regimens in Multiple Myeloma

Philippe.
Professor Moreau gave a wonderful presentation

Co-chaired by Professor Chen Zixing of the First Affiliated Hospital of Soochow University and Professor Fu Chengcheng of the First Affiliated Hospital of Soochow University, Philippe.
Professor Moreau explained Induction Regimens in Multiple Myeloma
.

In patients with newly diagnosed multiple myeloma (NDMM) suitable for transplantation, the results of the study showed that the addition of daratumab + bortezomib + thalidomide + dexamethasone (D-VTd) versus bortezomib + thalidomide + dexamethasone (VTd) regimen showed that the addition of daratumumab to the VTd regimen improved the depth of
remission.
In recent years, multiple studies have demonstrated that the D-VTd regimen has a better depth of response than the VTd regimen in all multiple myeloma (MM) subgroups, including the high-risk cytogenetics subgroup
.
At the same time, daratumab + bortezomib + melphalan + prednisone (D-VMP) regimens also showed significant progression-free survival (PFS) benefit, and patients treated with D-VMP regimens had a 40%
lower risk of death.
In addition, daratumumab + lenalidomide + dexamethasone (D-Rd) was deeper
than the Rd regimen-induced remission.

Pharmacological Aspects on Pretransplant Conditioning Therapy-AML

Professor Borje S.
Andersson gave a wonderful presentation

Professor Sun Zimin of the First Affiliated Hospital of University of Science and Technology of China and Professor Tang Xiaowen of the First Affiliated Hospital of Soochow University, Professor Borje S.
Andersson gave a special report
on "Pharmacological Aspects on Pretransplant Conditioning Therapy-AML".

In recent years, Professor Borje S.
Andersson has focused on research on less toxic and more effective pre-transplant pretreatment regimens, and developed the first FDA-approved cytotoxic drug for pre-transplant pretreatment treatment, busultan injection
.
In addition, the combination therapy of busulfan injection and fludarabine has quickly become the new standard
of care before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloid malignancies.
In the future, the development of less toxic pre-transplant treatment regimens and the addition of newer nucleoside analogues, such as clofarabine and gemcitabine, to pre-transplant treatment, has greatly improved the safety of stem cell transplantation, helped patients to carry out personalized treatment, and improved prognosis
.

epilogue

Stepping on the mountains, rivers, stars and moons as lights, look at the present and strive for excellence
.
The 2022 Suzhou Hematology Summit brought together top hematology experts at home and abroad to conduct in-depth discussions
on the research and development of new hematology drugs, precision medicine and leukemia, big data platform construction, and blood innovation forum.
On the occasion of the 73rd anniversary of the National Day, the 20th National Congress of the Communist Party of China was convened, and the country and the nation embarked on a new great journey
.
China's hematologists will unite as one, shoulder the mission of Healthy China with the expectations of blood patients, and work hard for the implementation of the "Healthy China 2030" Planning Outline! Many hematologists will take dreams as horses and stars and moons as lamps to continue to inherit the spirit of serving patients with blood diseases, so that the development of hematology in China will continue to innovate and create more brilliance!